Data from other studies in patients with acute coronary syndrome [40] and other cardiovascular disease [41] indicated that the clinical impact of circulating Ang-1 –in contrast to other angiopoietins—is probably small. This evidence concerns the gene ANGPT1 and acute coronary syndrome.